Gene editing, particularly the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas9 system, is now being extensively used in drug discovery for disease modeling, functional screening, target identification and more. Cambridge Healthtech Institute’s conference on CRISPR for Disease Modeling and Target Discovery will bring together experts, from target discovery to functional screening, to talk about how CRISPR is being used to unravel cellular pathways in disease and identify potential targets for drug intervention. This is a unique opportunity to hear from experts in pharma/biotech, academic and government labs specifically about their experiences leveraging the utility of CRISPR-based gene editing to create relevant cell lines, knock-outs and in vivo tools for modeling diseases, identifying and validating targets, functional screening, epigenome engineering, and more. It’s also an opportunity that brings together users and solution providers to talk about ways to overcome some of the inherent challenges in specificity, efficiency, delivery and off-target effects, associated with CRISPR/Cas9.
- CRISPR for Disease Modeling and Target Discovery
- CRISPR-based functional & phenotypic screens
- Unraveling disease pathways using CRISPR/Cas9
- CRISPR for target identification
|Date||26 Sep 2017|
|Location||The Westin Copley Place|
Boston, Massachusetts, USA